A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs
Article Abstract:
Bioanalytical assessments of anti-drug antibodies (ADAs) is necessary for understanding of the immunogencity of biological drug molecules. A new general strategy to broadly assign immunogenicity risk levels to biological drug products and present risk-level based bioanalytical schemes for the investigations of treatment related ADAs in clinical and nonclinical studies are described.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
Two heads are better than one
Article Abstract:
The generation of bispecific antibodies that have simultaneously recognized two different molecules is explored. The production of bispecific, tetravalent antibodies of different binding specificities has shown that these agents might prove to become clinically important.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: An essential role for Akt1 in dendritic cell function and tumor immunotherapy. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity
- Abstracts: RISC control for gene therapy. Isotype selection in antibody engineering. Antibodies in the breakdown lane
- Abstracts: Anthony Atala. Isolation of amniotic stem cell lines with potential for therapy
- Abstracts: Reversal of mouse hepatic failure using an implanted liver-assist device containing ES cell-derived hepatocytes